Loading...

Brilliant Violet 711™ anti-human CD8a Antibody

Pricing & Availability
Clone
RPA-T8 (See other available formats)
Regulatory Status
RUO
Workshop
IV T171
Other Names
T8, Leu2
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
RPA-T8_BV711_061412
Human peripheral blood lymphocytes were stained with CD3 FITC and CD8 (clone RPA-T8) Brilliant Violet 711™.
  • RPA-T8_BV711_061412
    Human peripheral blood lymphocytes were stained with CD3 FITC and CD8 (clone RPA-T8) Brilliant Violet 711™.
See Brilliant Violet 711™ spectral data
Cat # Size Price Quantity Check Availability Save
301043 25 tests 165€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
301044 100 tests 317€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8a is a 32-34 kD type I glycoprotein. It forms a homodimer (CD8a/a) or heterodimer (CD8a/b) with CD8b. CD8, also known as T8 and Leu2, is a member of the immunoglobulin superfamily found on the majority of thymocytes, a subset of peripheral blood T cells, and NK cells (which express almost exclusively CD8a homodimers). CD8 acts as a co-receptor with MHC class I-restricted T cell receptors in antigen recognition and T cell activation, and has been shown to play a role in thymic differentiation. Two domains in CD8a are important for function: the extracellular IgSF domain binds the α3 domain of MHC class I and the cytoplasmic CXCP motif binds the tyrosine kinase p56 Lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Human,Cynomolgus,Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 711™ under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 711™ excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 711™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The RPA-T8 antibody does not block the binding of HIT8a antibody to CD8a. Additional reported applications of this antibody (for the relevant formats) include: immunohistochemical staining of paraformaldehyde-fixed frozen sections3 and costimulation of T cell responses4. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 301073 & 301074).

Application References
  1. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  3. Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC)
  4. Magidovich E, et al. 2007. P. Natl. Acad. Sci. USA 104:13022.
  5. Thakarl D, et al. 2008.J. immunol. 180:7431. PubMed
  6. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
  7. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
  8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  9. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
  10. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
Product Citations
  1. Medler TR et al. 2018. Cancer cell. 34(4):561-578 . PubMed
  2. Ollé Hurtado M, et al. 2019. PLoS One. 14:e0216373. PubMed
  3. Cale EM et al. 2017. Immunity. 46(5):777-791 . PubMed
  4. Krebs SJ, et al. 2019. Immunity. 50:677. PubMed
  5. Serwas NK, et al. 2019. Nat Commun. 2.573611111. PubMed
  6. Om K, et al. 2020. PLoS Pathog. 16:e1008764. PubMed
  7. Cartwright E, et al. 2014. J Immunol. 192:4666. PubMed
  8. Chowdhury A, et al. 2015. J Virol. 89: 8677-8686. PubMed
  9. Demers K, et al. 2016. PLoS Pathog. 12: 1005805. PubMed
  10. Calascibetta F, et al. 2016. J Virol. 90: 7541 - 7551. PubMed
  11. Waddington KE, et al. 2020. Front Immunol. 1.51875. PubMed
  12. Gurusamy D, et al. 2020. Cancer Cell. 37(6):818-833.e9. PubMed
  13. Buggert M, et al. 2020. Cell. 183(7):1946-1961.e15. PubMed
  14. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  15. Mandolesi M, et al. 2021. Cell Reports Medicine. 2(4):100252. PubMed
  16. Singh KS, et al. 2021. Nature. 589:597. PubMed
  17. Misheva M, et al. 2022. Nat Commun. 13:139. PubMed
  18. Iwamoto N, et al. 2021. PLoS One. 16:e0248973. PubMed
  19. Ahmed R, et al. 2020. Cell Rep. 33:108501. PubMed
  20. Rajamanickam V, et al. 2021. Cancer Immunol Res. 9:602. PubMed
  21. Gao Y, et al. 2022. Immunity. 55:1732. PubMed
  22. Cook CP, et al. 2022. Cell Rep Med. 3:100715. PubMed
  23. Touizer E, et al. 2023. iScience. 26:105862. PubMed
  24. Statzu M, et al. 2023. Nat Microbiol. 8:299. PubMed
  25. Beck C, et al. 2023. Biomedicines. 11:. PubMed
RRID
AB_11218793 (BioLegend Cat. No. 301043)
AB_2562906 (BioLegend Cat. No. 301044)

Antigen Details

Structure
Ig superfamily, homodimer or heterodimer with CD8β, 32-34 kD
Distribution

Majority of thymocytes, T cell subset, NK cells

Function
MHC class I co-receptor, thymic differentiation, T cell activation
Ligand/Receptor
MHC Class I molecules
Cell Type
Dendritic cells, NK cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay N, et al. 1993. The Leucocyte Antigen FactsBook. Academic Press Inc. San Diego.

Gene ID
925 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 3    Revision Date: 07/13/2015

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account